{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:51:09Z","timestamp":1782118269113,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ajo.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:40:32Z","timestamp":1770828032000},"page":"261-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Trouble With Photodynamic Therapy"],"prefix":"10.1016","volume":"285","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0442-8122","authenticated-orcid":false,"given":"David J.","family":"Browning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2026.02.002_bib0001","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/archopht.1995.01100060136048","article-title":"Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin","volume":"113","author":"Miller","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.02.002_bib0002","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials\u2014TAP report","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.002_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2014VIP report no. 3","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2026.02.002_bib0004","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ophtha.2004.02.014","article-title":"Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study","volume":"111","author":"Rosenfeld","year":"2004","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.02.002_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3928\/23258160-20121221-07","article-title":"Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome","volume":"44","author":"Ramaiya","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.002_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.ajo.2026.02.002_bib0007","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajo.2026.02.002_bib0008","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","article-title":"Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial","volume":"115","author":"Chan","year":"2008","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2026.02.002_bib0009","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.02.002_bib0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2008.08.029","article-title":"Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma","volume":"116","author":"Boixadera","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2026.02.002_bib0011","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.oret.2023.10.024","article-title":"Comparing half-dose photodynamic therapy with subthreshold micropulse laser for the treatment of central serous chorioretinopathy","volume":"8","author":"Brelen","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"10.1016\/j.ajo.2026.02.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.0859","article-title":"Measuring the scope of prior authorization policies: applying private insurer rules to Medicare Part B","volume":"2","author":"Schwartz","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.ajo.2026.02.002_bib0013","unstructured":"Lo J, Long M, Wallace R, Salaga M, Pestaina K. Claims denials and appeals in ACA marketplace plans in 2023. Accessed January 27, 2025. https:\/\/www.kff.org\/private-insurance\/issue-brief\/claims-denials-and-appeals-in-aca-marketplace-plans-in-2023\/"},{"issue":"5","key":"10.1016\/j.ajo.2026.02.002_bib0014","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.02.002_bib0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1524-4733.2007.00206.x","article-title":"Prices for innovative pharmaceutical productsthat provide health gain: a comparison between Australia and the United States","volume":"10","author":"Roughhead","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.ajo.2026.02.002_bib0016","unstructured":"Drugs.com. Generic Visudyne availability. Secondary generic Visudyne availability. Accessed February 16, 2026. https:\/\/www.drugs.com\/availability\/generic-visudyne.html"},{"key":"10.1016\/j.ajo.2026.02.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2023.103501","article-title":"Anatomical and functional impact of verteporfin shortage in patients with chronic central serous chorioretinopathy","volume":"42","author":"Oribio-Quinto","year":"2023","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"7","key":"10.1016\/j.ajo.2026.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40123-024-00952-9","article-title":"Perspectives and update on the global shortage of verteporfin (Visudyne((R)))","volume":"13","author":"Sirks","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ajo.2026.02.002_bib0019","series-title":"Ophthalmol Manag","article-title":"Medicare fraud & abuse issues in OASC reimbursement","author":"Asbell","year":"2013"},{"issue":"1","key":"10.1016\/j.ajo.2026.02.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48825-7","article-title":"Association between visual function and the integrity of residual ellipsoid zone in resolved central serous chorioretinopathy","volume":"9","author":"Fujita","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ajo.2026.02.002_bib0021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2026.02.002_bib0022","unstructured":"Fournier D, Riley T, Bartlett M. Can we please stop fixating on hospital chargemasters? Accessed May 26, 2025. https:\/\/nashp.org\/can-we-please-stop-fixating-on-hospital-chargemasters"},{"issue":"9","key":"10.1016\/j.ajo.2026.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1377\/hlthaff.2016.0093","article-title":"US hospitals are still using chargemaster markups to maximize revenues","volume":"35","author":"Bai","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ajo.2026.02.002_bib0025","unstructured":"McMorrow S, Berenson RA, Holahan J. Commercial health insurance markups over Medicare prices for physician services vary widely by specialty. Accessed May 26, 2025. https:\/\/www.urban.org\/sites\/default\/files\/publication\/104945\/commercial-health-insurance-markups-over-medicare-prices-for-physician-services-vary-widely-by-specialty.pdf"},{"issue":"9","key":"10.1016\/j.ajo.2026.02.002_bib0026","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/bjo.2003.023986","article-title":"Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case","volume":"88","author":"Smith","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.02.002_bib0027","unstructured":"Eye 7 Eye Hospitals. Vitreoretinal procedures PDT photodynamic therapy and verteporfin with cost of dye single eye cost in India. Accessed February 27, 2026. https:\/\/www.eye7.in\/eye-treatments\/photodynamic-therapy\/."},{"key":"10.1016\/j.ajo.2026.02.002_bib0029","series-title":"Review of drugs approved via the 505(b)(2) pathway: uncovering drug development trends and regulatory requirements","year":"2025"},{"key":"10.1016\/j.ajo.2026.02.002_bib0030","unstructured":"Medicare Learning Network, MLN Matters. Compendia as authoritative sources for use in the determination of a \u201cmedically accepted indication\u201d of drugs and biologicals used off-label in an anti-cancer chemotherapeutic regimen. 2008. Accessed May 26, 2025. https:\/\/www.cms.gov\/outreach-and-education\/medicare-learning-network-mln\/mlnmattersarticles\/downloads\/mm6191.pdf"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.002_bib0031","article-title":"Employment: physician not protected from termination for advocating medically appropriate health care\u2014Khajavi v. Feather River Anesthesia Medical Group","volume":"26","author":"Arnold","year":"2000","journal-title":"Am J Law Med"},{"key":"10.1016\/j.ajo.2026.02.002_bib0032","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ceo.14201","article-title":"Central serous retinopathy: a review","volume":"51","author":"Fung","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2026.02.002_bib0033","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/s41433-022-02370-2","article-title":"Real world outcomes of photodynamic therapy for chronic central serous chorioretinopathy","volume":"37","author":"Khandhadia","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajo.2026.02.002_bib0034","series-title":"Research and development in the pharmaceutical industry","year":"2021"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:27:13Z","timestamp":1782116833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426000590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["S0002939426000590"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.02.002","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Trouble With Photodynamic Therapy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}